سوق التهاب الجلد العالمي - اتجاهات الصناعة والتوقعات حتى عام 2029

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL DERMATITIS MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATION

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 KEY TAKEAWAYS

2.2 ARRIVING AT THE GLOBAL DERMATITIS MARKET SIZE

2.2.1 VENDOR POSITIONING GRID

2.2.2 TECHNOLOGY LIFE LINE CURVE

2.2.3 TRIPOD DATA VALIDATION MODEL

2.2.4 MARKET GUIDE

2.2.5 MULTIVARIATE MODELLING

2.2.6 TOP TO BOTTOM ANALYSIS

2.2.7 CHALLENGE MATRIX

2.2.8 APPLICATION COVERAGE GRID

2.2.9 STANDARDS OF MEASUREMENT

2.2.10 VENDOR SHARE ANALYSIS

2.2.11 EPIDEMIOLOGY MODELING

2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS

2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES

2.3 GLOBAL DERMATITIS MARKET: RESEARCH SNAPSHOT

2.4 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTER'S 5 FORCES

4.2 PESTEL ANALYSIS

5 EPIDEMIOLOGY

5.1 PREVALECE OF ATOPIC DERMATITIS, BY COUNTRY

5.2 PREVALECE OF CONTACT DERMATITIS, BY COUNTRY

5.3 PREVALECE OF DYSHIDROTIC DERMATITIS, BY COUNTRY

5.4 PREVALECE OF SEBORRHEIC DERMATITIS, BY COUNTRY

5.5 PREVALECE OF ATOPIC DERMATITIS, BY COUNTRY

5.6 PREVALECE OF STASIS DERMATITIS, BY COUNTRY

5.7 TREATMENT RATE

5.8 MORTALITY RATE

5.9 DRUG ADHERENCE AND THERAPY SWITCH MODEL

5.1 PATEINT TREATMENT SUCCESS RATES

6 INDUSTRY INSIGHTS

6.1 PATENT ANALYSIS

6.2 DRUG TREATMENT RATE BY MATURED MARKETS

6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES

6.4 PATIENT FLOW DIAGRAM

6.5 KEY PRICING STRATEGIES

6.6 KEY PATIENT ENROLLMENT STRATEGIES

6.7 INTERVIEWS WITH DERMATOLOGIST

6.8 OTHER KOL SNAPSHOTS

7 REGULATORY SCENARIO

7.1 FDA APPROVALS

7.2 EMA APPROVALS

8 MERGERS AND ACQUISITION

8.1 LICENSING

8.2 COMMERCIALIZATION AGREEMENTS

9 PIPELINE ANALYSIS

9.1 CLINICAL TRIALS AND PHASE ANALYSIS

9.2 DRUG THERAPY PIPELINE

9.3 PHASE III CANDIDATES

9.3.1 BARICITNIB

9.3.2 UPADACITNIB

9.3.3 RUXOLITIIB

9.3.4 ABROCITNIB

9.3.5 NEMOLIZUMAB

9.3.6 LEBRIKIZUMAB

9.3.7 KHK-4083

9.3.8 OTHERS

9.4 PHASE II CANDIDATES

9.4.1 TOFACITNIB

9.4.2 GUSACITNIB

9.4.3 RISANKIZUMAB

9.4.4 BERMEKIMAB

9.4.5 OTHERS

9.5 PHASE I CANDIDATES

9.6 OTHERS (PRE-CLINICAL AND RESEARCH)

10 MARKET OVERVIEW

10.1 DRIVERS

10.2 RESTRAINS

10.3 OPPURTUNITY

10.4 CHALLENGES

11 GLOBAL DERMATITIS MARKET, BY TREATMENT

11.1 OVERVIEW

11.2 PHOSPHODIESTERASE-4 INHIBITORS

11.2.1 BY DRUGS

11.2.1.1. APREMILAST

11.2.1.1.1. MARKET VALUE (USD MN)

11.2.1.1.2. MARKET VOLUME (IU)

11.2.1.1.3. AVERAGE SELLING PRICE (USD)

11.2.1.2. CRISABOROLE

11.2.1.2.1. MARKET VALUE (USD MN)

11.2.1.2.2. MARKET VOLUME (IU)

11.2.1.2.3. AVERAGE SELLING PRICE (USD)

11.2.1.3. ROFLUMILAST

11.2.1.3.1. MARKET VALUE (USD MN)

11.2.1.3.2. MARKET VOLUME (IU)

11.2.1.3.3. AVERAGE SELLING PRICE (USD)

11.2.1.4. OTHERS

11.2.2 BY DRUG TYPE

11.2.2.1. GENERICS

11.2.2.2. BRANDED

11.2.2.2.1. OTEZLA

11.2.2.2.1.1 MARKET VALUE (USD MN)

11.2.2.2.1.2 MARKET VOLUME (IU)

11.2.2.2.1.3 AVERAGE SELLING PRICE (USD)

11.2.2.2.2. EUCRIS

11.2.2.2.2.1 MARKET VALUE (USD MN)

11.2.2.2.2.2 MARKET VOLUME (IU)

11.2.2.2.2.3 AVERAGE SELLING PRICE (USD)

11.2.2.2.3. DAXAS

11.2.2.2.3.1 MARKET VALUE (USD MN)

11.2.2.2.3.2 MARKET VOLUME (IU)

11.2.2.2.3.3 AVERAGE SELLING PRICE (USD)

11.2.2.2.4. OTHERS

11.3 CALCINEURIN INHIBITORS

11.3.1 BY DRUGS

11.3.1.1. TACROLIMUS

11.3.1.1.1. MARKET VALUE (USD MN)

11.3.1.1.2. MARKET VOLUME (IU)

11.3.1.1.3. AVERAGE SELLING PRICE (USD)

11.3.1.2. PIMCROMILUS

11.3.1.2.1. MARKET VALUE (USD MN)

11.3.1.2.2. MARKET VOLUME (IU)

11.3.1.2.3. AVERAGE SELLING PRICE (USD)

11.3.1.3. OTHERS

11.3.2 BY DRUG TYPE

11.3.2.1. GENERICS

11.3.2.2. BRANDED

11.3.2.2.1. PROTOPIC

11.3.2.2.1.1 MARKET VALUE (USD MN)

11.3.2.2.1.2 MARKET VOLUME (IU)

11.3.2.2.1.3 AVERAGE SELLING PRICE (USD)

11.3.2.2.2. ELIDEL

11.3.2.2.2.1 MARKET VALUE (USD MN)

11.3.2.2.2.2 MARKET VOLUME (IU)

11.3.2.2.2.3 AVERAGE SELLING PRICE (USD)

11.3.2.2.3. OTHERS

11.4 BIOLOGICS

11.4.1 DUPLIMAB

11.4.1.1. MARKET VALUE (USD MN)

11.4.1.2. MARKET VOLUME (IU)

11.4.1.3. AVERAGE SELLING PRICE (USD)

11.4.2 TRALOKINUMAB

11.4.2.1. MARKET VALUE (USD MN)

11.4.2.2. MARKET VOLUME (IU)

11.4.2.3. AVERAGE SELLING PRICE (USD)

11.4.3 OTHERS

11.5 SOOTHING PRODUCTS

11.5.1 CALAMINE LOTION

11.5.1.1. MARKET VALUE (USD MN)

11.5.1.2. MARKET VOLUME (IU)

11.5.1.3. AVERAGE SELLING PRICE (USD)

11.5.2 COLLOIDAL OATMEAL

11.5.2.1. MARKET VALUE (USD MN)

11.5.2.2. MARKET VOLUME (IU)

11.5.2.3. AVERAGE SELLING PRICE (USD)

11.5.3 OTHERS

11.6 CORTICOSTEROIDS

11.6.1 BY DRUGS

11.6.1.1. BETAMETHASONE

11.6.1.1.1. MARKET VALUE (USD MN)

11.6.1.1.2. MARKET VOLUME (IU)

11.6.1.1.3. AVERAGE SELLING PRICE (USD)

11.6.1.2. CLOBETASOL

11.6.1.2.1. MARKET VALUE (USD MN)

11.6.1.2.2. MARKET VOLUME (IU)

11.6.1.2.3. AVERAGE SELLING PRICE (USD)

11.6.1.3. FLUOCINONIDE

11.6.1.3.1. MARKET VALUE (USD MN)

11.6.1.3.2. MARKET VOLUME (IU)

11.6.1.3.3. AVERAGE SELLING PRICE (USD)

11.6.1.4. HALOBETASOL

11.6.1.4.1. MARKET VALUE (USD MN)

11.6.1.4.2. MARKET VOLUME (IU)

11.6.1.4.3. AVERAGE SELLING PRICE (USD)

11.6.1.5. FLURANDRENOLIDE

11.6.1.5.1. MARKET VALUE (USD MN)

11.6.1.5.2. MARKET VOLUME (IU)

11.6.1.5.3. AVERAGE SELLING PRICE (USD)

11.6.1.6. AMCINONIDE

11.6.1.6.1. MARKET VALUE (USD MN)

11.6.1.6.2. MARKET VOLUME (IU)

11.6.1.6.3. AVERAGE SELLING PRICE (USD)

11.6.1.7. HYDROCORTISONE

11.6.1.7.1. MARKET VALUE (USD MN)

11.6.1.7.2. MARKET VOLUME (IU)

11.6.1.7.3. AVERAGE SELLING PRICE (USD)

11.6.1.8. TRIAMCINOLONE

11.6.1.8.1. MARKET VALUE (USD MN)

11.6.1.8.2. MARKET VOLUME (IU)

11.6.1.8.3. AVERAGE SELLING PRICE (USD)

11.6.1.9. OTHERS

11.6.2 BY DRUG TYPE

11.6.2.1. GENERICS

11.6.2.2. BRANDED

11.6.2.2.1. CELESTONE

11.6.2.2.1.1 MARKET VALUE (USD MN)

11.6.2.2.1.2 MARKET VOLUME (IU)

11.6.2.2.1.3 AVERAGE SELLING PRICE (USD)

11.6.2.2.2. TEMOVATE

11.6.2.2.2.1 MARKET VALUE (USD MN)

11.6.2.2.2.2 MARKET VOLUME (IU)

11.6.2.2.2.3 AVERAGE SELLING PRICE (USD)

11.6.2.2.3. VANOS

11.6.2.2.3.1 MARKET VALUE (USD MN)

11.6.2.2.3.2 MARKET VOLUME (IU)

11.6.2.2.3.3 AVERAGE SELLING PRICE (USD)

11.6.2.2.4. CYCLOCORT

11.6.2.2.4.1 MARKET VALUE (USD MN)

11.6.2.2.4.2 MARKET VOLUME (IU)

11.6.2.2.4.3 AVERAGE SELLING PRICE (USD)

11.6.2.2.5. ULTRAVATE

11.6.2.2.5.1 MARKET VALUE (USD MN)

11.6.2.2.5.2 MARKET VOLUME (IU)

11.6.2.2.5.3 AVERAGE SELLING PRICE (USD)

11.6.2.2.6. HYDROCORT

11.6.2.2.6.1 MARKET VALUE (USD MN)

11.6.2.2.6.2 MARKET VOLUME (IU)

11.6.2.2.6.3 AVERAGE SELLING PRICE (USD)

11.6.2.2.7. ALPHOSYL

11.6.2.2.7.1 MARKET VALUE (USD MN)

11.6.2.2.7.2 MARKET VOLUME (IU)

11.6.2.2.7.3 AVERAGE SELLING PRICE (USD)

11.6.2.2.8. KENALOG

11.6.2.2.8.1 MARKET VALUE (USD MN)

11.6.2.2.8.2 MARKET VOLUME (IU)

11.6.2.2.8.3 AVERAGE SELLING PRICE (USD)

11.6.2.2.9. ARISTOSPAN

11.6.2.2.9.1 MARKET VALUE (USD MN)

11.6.2.2.9.2 MARKET VOLUME (IU)

11.6.2.2.9.3 AVERAGE SELLING PRICE (USD)

11.6.2.2.10. OTHERS

11.7 ANTIHISTAMINES

11.7.1 BY DRUGS

11.7.1.1. DIPHENHYDRAMINE

11.7.1.1.1. MARKET VALUE (USD MN)

11.7.1.1.2. MARKET VOLUME (IU)

11.7.1.1.3. AVERAGE SELLING PRICE (USD)

11.7.1.2. CHLORPHENIRAMINE

11.7.1.2.1. MARKET VALUE (USD MN)

11.7.1.2.2. MARKET VOLUME (IU)

11.7.1.2.3. AVERAGE SELLING PRICE (USD)

11.7.1.3. CLEMASTINE

11.7.1.3.1. MARKET VALUE (USD MN)

11.7.1.3.2. MARKET VOLUME (IU)

11.7.1.3.3. AVERAGE SELLING PRICE (USD)

11.7.1.4. FEXOFENADINE

11.7.1.4.1. MARKET VALUE (USD MN)

11.7.1.4.2. MARKET VOLUME (IU)

11.7.1.4.3. AVERAGE SELLING PRICE (USD)

11.7.1.5. LORATADINE

11.7.1.5.1. MARKET VALUE (USD MN)

11.7.1.5.2. MARKET VOLUME (IU)

11.7.1.5.3. VERAGE SELLING PRICE (USD)

11.7.1.6. CETRIZINE

11.7.1.6.1. MARKET VALUE (USD MN)

11.7.1.6.2. MARKET VOLUME (IU)

11.7.1.6.3. AVERAGE SELLING PRICE (USD)

11.7.1.7. CLEMASTINE

11.7.1.7.1. MARKET VALUE (USD MN)

11.7.1.7.2. MARKET VOLUME (IU)

11.7.1.7.3. AVERAGE SELLING PRICE (USD)

11.7.1.8. OTHERS

11.7.2 BY DRUG TYPE

11.7.2.1. GENERICS

11.7.2.2. BRANDED

11.7.2.2.1. DYTAN DM

11.7.2.2.1.1 MARKET VALUE (USD MN)

11.7.2.2.1.2 MARKET VOLUME (IU)

11.7.2.2.1.3 AVERAGE SELLING PRICE (USD)

11.7.2.2.2. CHLOR TRIMETON

11.7.2.2.2.1 MARKET VALUE (USD MN)

11.7.2.2.2.2 MARKET VOLUME (IU)

11.7.2.2.2.3 AVERAGE SELLING PRICE (USD)

11.7.2.2.3. TAVIST ALLERGY

11.7.2.2.3.1 MARKET VALUE (USD MN)

11.7.2.2.3.2 MARKET VOLUME (IU)

11.7.2.2.3.3 AVERAGE SELLING PRICE (USD)

11.7.2.2.4. ALLEGRA

11.7.2.2.4.1 MARKET VALUE (USD MN)

11.7.2.2.4.2 MARKET VOLUME (IU)

11.7.2.2.4.3 AVERAGE SELLING PRICE (USD)

11.7.2.2.5. CLARITIN

11.7.2.2.5.1 MARKET VALUE (USD MN)

11.7.2.2.5.2 MARKET VOLUME (IU)

11.7.2.2.5.3 AVERAGE SELLING PRICE (USD)

11.7.2.2.6. ZYRTEC

11.7.2.2.6.1 MARKET VALUE (USD MN)

11.7.2.2.6.2 MARKET VOLUME (IU)

11.7.2.2.6.3 AVERAGE SELLING PRICE (USD)

11.7.2.2.7. OTHERS

11.8 ANTIBIOTICS

11.8.1 BY DRUGS

11.8.1.1. ERYTHROMYCIN

11.8.1.1.1. MARKET VALUE (USD MN)

11.8.1.1.2. MARKET VOLUME (IU)

11.8.1.1.3. AVERAGE SELLING PRICE (USD)

11.8.1.2. SULFACETAMIDE

11.8.1.2.1. MARKET VALUE (USD MN)

11.8.1.2.2. MARKET VOLUME (IU)

11.8.1.2.3. AVERAGE SELLING PRICE (USD)

11.8.1.3. NEOMYCIN

11.8.1.3.1. MARKET VALUE (USD MN)

11.8.1.3.2. MARKET VOLUME (IU)

11.8.1.3.3. AVERAGE SELLING PRICE (USD)

11.8.1.4. VANCOMYCIN

11.8.1.4.1. MARKET VALUE (USD MN)

11.8.1.4.2. MARKET VOLUME (IU)

11.8.1.4.3. AVERAGE SELLING PRICE (USD)

11.8.1.5. LINEZOLID

11.8.1.5.1. MARKET VALUE (USD MN)

11.8.1.5.2. MARKET VOLUME (IU)

11.8.1.5.3. AVERAGE SELLING PRICE (USD)

11.8.1.6. CEFTAROLINE

11.8.1.6.1. MARKET VALUE (USD MN)

11.8.1.6.2. MARKET VOLUME (IU)

11.8.1.6.3. AVERAGE SELLING PRICE (USD)

11.8.1.7. DAPTOMYCIN

11.8.1.7.1. MARKET VALUE (USD MN)

11.8.1.7.2. MARKET VOLUME (IU)

11.8.1.7.3. AVERAGE SELLING PRICE (USD)

11.8.1.8. OFLOXACIN

11.8.1.8.1. MARKET VALUE (USD MN)

11.8.1.8.2. MARKET VOLUME (IU)

11.8.1.8.3. AVERAGE SELLING PRICE (USD)

11.8.1.9. CIPROFLOXACIN

11.8.1.9.1. MARKET VALUE (USD MN)

11.8.1.9.2. MARKET VOLUME (IU)

11.8.1.9.3. AVERAGE SELLING PRICE (USD)

11.8.1.10. OTHERS

11.8.2 BY DRUG TYPE

11.8.2.1. GENERICS

11.8.2.2. BRANDED

11.8.2.2.1. KLARON

11.8.2.2.1.1 MARKET VALUE (USD MN)

11.8.2.2.1.2 MARKET VOLUME (IU)

11.8.2.2.1.3 AVERAGE SELLING PRICE (USD)

11.8.2.2.2. OVACE

11.8.2.2.2.1 MARKET VALUE (USD MN)

11.8.2.2.2.2 MARKET VOLUME (IU)

11.8.2.2.2.3 AVERAGE SELLING PRICE (USD)

11.8.2.2.3. VANCOCIN

11.8.2.2.3.1 MARKET VALUE (USD MN)

11.8.2.2.3.2 MARKET VOLUME (IU)

11.8.2.2.3.3 AVERAGE SELLING PRICE (USD)

11.8.2.2.4. ZYVOX

11.8.2.2.4.1 MARKET VALUE (USD MN)

11.8.2.2.4.2 MARKET VOLUME (IU)

11.8.2.2.4.3 AVERAGE SELLING PRICE (USD)

11.8.2.2.5. TEFLARO

11.8.2.2.5.1 MARKET VALUE (USD MN)

11.8.2.2.5.2 MARKET VOLUME (IU)

11.8.2.2.5.3 AVERAGE SELLING PRICE (USD)

11.8.2.2.6. CUBICIN

11.8.2.2.6.1 MARKET VALUE (USD MN)

11.8.2.2.6.2 MARKET VOLUME (IU)

11.8.2.2.6.3 AVERAGE SELLING PRICE (USD)

11.8.2.2.7. FLOXIN

11.8.2.2.7.1 MARKET VALUE (USD MN)

11.8.2.2.7.2 MARKET VOLUME (IU)

11.8.2.2.7.3 AVERAGE SELLING PRICE (USD)

11.8.2.2.8. CIPRO

11.8.2.2.8.1 MARKET VALUE (USD MN)

11.8.2.2.8.2 MARKET VOLUME (IU)

11.8.2.2.8.3 AVERAGE SELLING PRICE (USD)

11.8.2.2.9. OTHERS

12 GLOBAL DERMATITIS MARKET, BY ROUTE OF ADMINISTRATION

12.1 OVERVIEW

12.2 TOPICAL

12.2.1 CREAM

12.2.2 LOTION

12.2.3 OINTMENT

12.2.4 SPRAY

12.2.5 OTHERS

12.3 ORAL

12.3.1 TABLET

12.3.2 CALPSULES

12.3.3 SYRUP

12.3.4 OTHERS

12.4 OTHERS

12.5 RECONSTITUTE

13 GLOBAL DERMATITIS MARKET, BY END USER

13.1 OVERVIEW

13.2 HOSPITALS

13.3 DERMATOLOGY CLINICS

13.4 ACADEMIC AND RESEARCH INSTITUTES

13.5 OTHERS

14 GLOBAL DERMATITIS MARKET, BY DISTRIBUTION CHANNEL

14.1 OVERVIEW

14.2 HOSPITAL PHARMACY

14.3 ONLINE PHARMACY

14.4 RETAIL PHARMACY

15 GLOBAL DERMATITIS MARKET, BY GEOGRAPHY

15.1 GLOBAL DERMATITIS MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

15.2 NORTH AMERICA

15.2.1 U.S.

15.2.1.1. U.S. DERMATITIS MARKET, BY TREATMENT TYPE

15.2.1.2. U.S. DERMATITIS MARKET, BY ROUTE OF ADMINISTRATION

15.2.1.3. U.S. DERMATITIS MARKET, BY END USER

15.2.1.4. U.S. DERMATITIS MARKET, BY DISTRIBUTION CHANNEL

15.2.2 CANADA

15.2.3 MEXICO

15.2.4 DOMINICAN REPUBLIC

15.2.5 JAMAICA

15.2.6 PANAMA

15.3 EUROPE

15.3.1 GERMANY

15.3.2 FRANCE

15.3.3 U.K.

15.3.4 HUNGARY

15.3.5 LITHUANIA

15.3.6 AUSTRIA

15.3.7 IRELAND

15.3.8 NORWAY

15.3.9 POLAND

15.3.10 ITALY

15.3.11 SPAIN

15.3.12 RUSSIA

15.3.13 TURKEY

15.3.14 NETHERLANDS

15.3.15 SWITZERLAND

15.3.16 REST OF EUROPE

15.4 ASIA-PACIFIC

15.4.1 JAPAN

15.4.2 CHINA

15.4.3 TAIWAN

15.4.4 SOUTH KOREA

15.4.5 INDIA

15.4.6 AUSTRALIA

15.4.7 SINGAPORE

15.4.8 THAILAND

15.4.9 MALAYSIA

15.4.10 INDONESIA

15.4.11 PHILIPPINES

15.4.12 VIETNAM

15.4.13 REST OF ASIA-PACIFIC

15.5 SOUTH AMERICA

15.5.1 BRAZIL

15.5.2 ECUADOR

15.5.3 CHILE

15.5.4 COLOMBIA

15.5.5 VENEZUELA

15.5.6 ARGENTINA

15.5.7 PERU

15.5.8 CURAÇAO

15.5.9 PARAGUAY

15.5.10 URUGUAY

15.5.11 TRINIDAD AND TOBAGO

15.5.12 REST OF SOUTH AMERICA

15.6 MIDDLE EAST AND AFRICA

15.6.1 SOUTH AFRICA

15.6.2 SAUDI ARABIA

15.6.3 UAE

15.6.4 EGYPT

15.6.5 KUWAIT

15.6.6 ISRAEL

15.6.7 BOLIVIA

15.6.8 REST OF MIDDLE EAST AND AFRICA

15.7 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

16 GLOBAL DERMATITIS MARKET, SWOT AND DBMR ANALYSIS

17 GLOBAL DERMATITIS MARKET, COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: GLOBAL

17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

17.3 COMPANY SHARE ANALYSIS: EUROPE

17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

17.5 MERGERS & ACQUISITIONS

17.6 NEW PRODUCT DEVELOPMENT & APPROVALS

17.7 EXPANSIONS

17.8 REGULATORY CHANGES

17.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

18 GLOBAL DERMATITIS MARKET, COMPANY PROFILE

18.1 PFIZER, INC

18.1.1 COMPANY OVERVIEW

18.1.2 REVENUE ANALYSIS

18.1.3 GEOGRAPHIC PRESENCE

18.1.4 PRODUCT PORTFOLIO

18.1.5 RECENT DEVELOPMENTS

18.2 JOHNSON & JOHNSON (JANSSEN PHARMACEUTICALS)

18.2.1 COMPANY OVERVIEW

18.2.2 REVENUE ANALYSIS

18.2.3 GEOGRAPHIC PRESENCE

18.2.4 PRODUCT PORTFOLIO

18.2.5 RECENT DEVELOPMENTS

18.3 NOVARTIS AG

18.3.1 COMPANY OVERVIEW

18.3.2 REVENUE ANALYSIS

18.3.3 GEOGRAPHIC PRESENCE

18.3.4 PRODUCT PORTFOLIO

18.3.5 RECENT DEVELOPMENTS

18.4 AMGEN

18.4.1 COMPANY OVERVIEW

18.4.2 REVENUE ANALYSIS

18.4.3 GEOGRAPHIC PRESENCE

18.4.4 PRODUCT PORTFOLIO

18.4.5 RECENT DEVELOPMENTS

18.5 SANOFI

18.5.1 COMPANY OVERVIEW

18.5.2 REVENUE ANALYSIS

18.5.3 GEOGRAPHIC PRESENCE

18.5.4 PRODUCT PORTFOLIO

18.5.5 RECENT DEVELOPMENTS

18.6 BRISTOL MYERS SQUIBB

18.6.1 COMPANY OVERVIEW

18.6.2 REVENUE ANALYSIS

18.6.3 GEOGRAPHIC PRESENCE

18.6.4 PRODUCT PORTFOLIO

18.6.5 RECENT DEVELOPMENTS

18.7 BAYER AG

18.7.1 COMPANY OVERVIEW

18.7.2 REVENUE ANALYSIS

18.7.3 GEOGRAPHIC PRESENCE

18.7.4 PRODUCT PORTFOLIO

18.7.5 RECENT DEVELOPMENTS

18.8 ASTELLAS PHARMA INC

18.8.1 COMPANY OVERVIEW

18.8.2 REVENUE ANALYSIS

18.8.3 GEOGRAPHIC PRESENCE

18.8.4 PRODUCT PORTFOLIO

18.8.5 RECENT DEVELOPMENTS

18.9 REGENERON PHARMACEUTICALS, INC

18.9.1 COMPANY OVERVIEW

18.9.2 REVENUE ANALYSIS

18.9.3 GEOGRAPHIC PRESENCE

18.9.4 PRODUCT PORTFOLIO

18.9.5 RECENT DEVELOPMENTS

18.1 F-HOFFMANN LA ROCHE

18.10.1 COMPANY OVERVIEW

18.10.2 REVENUE ANALYSIS

18.10.3 GEOGRAPHIC PRESENCE

18.10.4 PRODUCT PORTFOLIO

18.10.5 RECENT DEVELOPMENTS

18.11 GLAXOSMITHKLINE PLC

18.11.1 COMPANY OVERVIEW

18.11.2 REVENUE ANALYSIS

18.11.3 GEOGRAPHIC PRESENCE

18.11.4 PRODUCT PORTFOLIO

18.11.5 RECENT DEVELOPMENTS

18.12 MERCK SHARP & DOHME CORP

18.12.1 COMPANY OVERVIEW

18.12.2 REVENUE ANALYSIS

18.12.3 GEOGRAPHIC PRESENCE

18.12.4 PRODUCT PORTFOLIO

18.12.5 RECENT DEVELOPMENTS

18.13 MYLAN NV

18.13.1 COMPANY OVERVIEW

18.13.2 REVENUE ANALYSIS

18.13.3 GEOGRAPHIC PRESENCE

18.13.4 PRODUCT PORTFOLIO

18.13.5 RECENT DEVELOPMENTS

18.14 TEVA PHARMACEUTICALS

18.14.1 COMPANY OVERVIEW

18.14.2 REVENUE ANALYSIS

18.14.3 GEOGRAPHIC PRESENCE

18.14.4 PRODUCT PORTFOLIO

18.14.5 RECENT DEVELOPMENTS

18.15 ASTRAZENCA

18.15.1 COMPANY OVERVIEW

18.15.2 REVENUE ANALYSIS

18.15.3 GEOGRAPHIC PRESENCE

18.15.4 PRODUCT PORTFOLIO

18.15.5 RECENT DEVELOPMENTS

18.16 AKORN

18.16.1 COMPANY OVERVIEW

18.16.2 REVENUE ANALYSIS

18.16.3 GEOGRAPHIC PRESENCE

18.16.4 PRODUCT PORTFOLIO

18.16.5 RECENT DEVELOPMENTS

18.17 BOEHRINGER INGELHEIM INTERNATIONAL GMBH

18.17.1 COMPANY OVERVIEW

18.17.2 REVENUE ANALYSIS

18.17.3 GEOGRAPHIC PRESENCE

18.17.4 PRODUCT PORTFOLIO

18.17.5 RECENT DEVELOPMENTS

18.18 CIPLA PHARMACEUTICALS

18.18.1 COMPANY OVERVIEW

18.18.2 REVENUE ANALYSIS

18.18.3 GEOGRAPHIC PRESENCE

18.18.4 PRODUCT PORTFOLIO

18.18.5 RECENT DEVELOPMENTS

18.19 OTSUKA PHARMACEUTICALS

18.19.1 COMPANY OVERVIEW

18.19.2 REVENUE ANALYSIS

18.19.3 GEOGRAPHIC PRESENCE

18.19.4 PRODUCT PORTFOLIO

18.19.5 RECENT DEVELOPMENTS

18.2 GALDERMA

18.20.1 COMPANY OVERVIEW

18.20.2 REVENUE ANALYSIS

18.20.3 GEOGRAPHIC PRESENCE

18.20.4 PRODUCT PORTFOLIO

18.20.5 RECENT DEVELOPMENTS

18.21 ARENA PHARMACEUTICALS

18.21.1 COMPANY OVERVIEW

18.21.2 REVENUE ANALYSIS

18.21.3 GEOGRAPHIC PRESENCE

18.21.4 PRODUCT PORTFOLIO

18.21.5 RECENT DEVELOPMENTS

18.22 ASANA BIOSCIENCES

18.22.1 COMPANY OVERVIEW

18.22.2 REVENUE ANALYSIS

18.22.3 GEOGRAPHIC PRESENCE

18.22.4 PRODUCT PORTFOLIO

18.22.5 RECENT DEVELOPMENTS

18.23 ZYDUS HEALTHCARE

18.23.1 COMPANY OVERVIEW

18.23.2 REVENUE ANALYSIS

18.23.3 GEOGRAPHIC PRESENCE

18.23.4 PRODUCT PORTFOLIO

18.23.5 RECENT DEVELOPMENTS

18.24 ABBVIE

18.24.1 COMPANY OVERVIEW

18.24.2 REVENUE ANALYSIS

18.24.3 GEOGRAPHIC PRESENCE

18.24.4 PRODUCT PORTFOLIO

18.24.5 RECENT DEVELOPMENTS

18.25 GENZYME PHARMA

18.25.1 COMPANY OVERVIEW

18.25.2 REVENUE ANALYSIS

18.25.3 GEOGRAPHIC PRESENCE

18.25.4 PRODUCT PORTFOLIO

18.25.5 RECENT DEVELOPMENTS

18.26 GILEAD SCIENCES

18.26.1 COMPANY OVERVIEW

18.26.2 REVENUE ANALYSIS

18.26.3 GEOGRAPHIC PRESENCE

18.26.4 PRODUCT PORTFOLIO

18.26.5 RECENT DEVELOPMENTS

18.27 ELI LILLY

18.27.1 COMPANY OVERVIEW

18.27.2 REVENUE ANALYSIS

18.27.3 GEOGRAPHIC PRESENCE

18.27.4 PRODUCT PORTFOLIO

18.27.5 RECENT DEVELOPMENTS

18.28 TAKEDA PHARMACEUTICALS

18.28.1 COMPANY OVERVIEW

18.28.2 REVENUE ANALYSIS

18.28.3 GEOGRAPHIC PRESENCE

18.28.4 PRODUCT PORTFOLIO

18.28.5 RECENT DEVELOPMENTS

18.29 UCB PHARMA

18.29.1 COMPANY OVERVIEW

18.29.2 REVENUE ANALYSIS

18.29.3 GEOGRAPHIC PRESENCE

18.29.4 PRODUCT PORTFOLIO

18.29.5 RECENT DEVELOPMENTS

18.3 EISAI CO

18.30.1 COMPANY OVERVIEW

18.30.2 REVENUE ANALYSIS

18.30.3 GEOGRAPHIC PRESENCE

18.30.4 PRODUCT PORTFOLIO

18.30.5 RECENT DEVELOPMENTS

NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST

19 RELATED REPORTS

20 CONCLUSION

21 QUESTIONNAIRE

22 ABOUT DATA BRIDGE MARKET RESEARCH